What Will Drive Regeneron Pharmaceuticals' Growth Higher From Here?
Regeneron Pharmaceuticals' (NASDAQ: REGN) $5 billion in sales in 2016 were due mostly to sales of its top-selling vision-restoring drug Eylea. However, a slate of newly Food and Drug Administration-approved drugs could provide significant revenue growth in the coming years. Sales of its bad cholesterol-lowering drug Praluent are starting to pick up, and the eczema drug Dupixent and rheumatoid arthritis drug Kevzara have recently launched.
In this clip from the Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes is joined by Todd Campbell to discuss the opportunities -- and the risks -- associated with Regeneron's newest products.
A full transcript follows the video.
Source: Fool.com
Amgen Inc. Stock
€278.20
-3.670%
The stock is an absolute favorite of our community with 24 Buy predictions and no Sell predictions.
With a target price of 296 € there is a slightly positive potential of 6.4% for Amgen Inc. compared to the current price of 278.2 €.
